-Newsclick.in A few weeks back Fortune magazine and CNN carried a long online blog titled ‘Dirty Medicine' by Dinesh Thakur, a former employ of Ranbaxy, where he recounts how he came across several procedural and other lapses in the company's manufacturing facilities. Since then the Fortune blog has become one of the most widely circulated and commented upon business stories in the world. The story received attention as it came in the...

-The Economic Times MUMBAI: The United States Food and Drug Administration (USFDA), widely considered the world's most stringent regulatory authority, has said India's share in generic exports to the US over the years is an indication of the good manufacturing norms practised by Indian drugmakers. As the Ranbaxy scandal threatens to tarnish India's image as a hub of manufacturing world-class generic drugs, the statement, by USFDA's spokesman Chris Kelly in an...

-The Economic Times India's GDP growth has almost halved from 9.2% in 2010-11 to 5% in 2012-12. Major problems include a high current account deficit, high fiscal deficit, and lack of bank credit for small and medium enterprises. All three problems can be mitigated substantially by one single measure - reducing excess food stocks. So say Ashok Gulati and Surabhi Jain, chairman and joint director respectively of the Commission for Agricultural...

-The Times of India A patch of wheat found growing in fallow field in Oregon, USA, has sent tremors across the world with some East Asian countries cancelling wheat import orders from the US, and the 27 member European Union to raise testing levels for US imports. The reason is that the wheat patch was found to be a genetically modified variety developed and tested by biotech giant Monsanto between 1999 and...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...